About the Authors
- Christian Stemberger
-
Contributed equally to this work with: Christian Stemberger, Stefan Dreher
Affiliations Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Focus Group “Clinical Cell Processing and Purification”, Institute for Advanced Study, Technische Universität München, Munich, Germany
- Stefan Dreher
-
Contributed equally to this work with: Christian Stemberger, Stefan Dreher
Affiliations Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Focus Group “Clinical Cell Processing and Purification”, Institute for Advanced Study, Technische Universität München, Munich, Germany
- Claudia Tschulik
-
Affiliation Stage Cell Therapeutics, Göttingen, Germany
- Christine Piossek
-
Affiliation Stage Cell Therapeutics, Göttingen, Germany
- Jeannette Bet
-
Affiliations Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Focus Group “Clinical Cell Processing and Purification”, Institute for Advanced Study, Technische Universität München, Munich, Germany
- Tori N. Yamamoto
-
Affiliation Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
- Matthias Schiemann
-
Affiliations Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Clinical Cooperation Group “Antigen-specific Immunotherapy”, Helmholtz Center Munich (Neuherberg) and TUM, Munich, Germany
- Michael Neuenhahn
-
Affiliations Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, DZIF - National Centre for Infection Research, Munich, Germany
- Klaus Martin
-
Affiliation Institute of Anaesthesiology, German Heart Center Munich, State of Bavaria and Technische Universität München, Munich, Germany
- Martin Schlapschy
-
Affiliation Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, Freising-Weihenstephan, Germany
- Arne Skerra
-
Affiliation Munich Center for Integrated Protein Science (CIPS-M) and Lehrstuhl für Biologische Chemie, Technische Universität München, Freising-Weihenstephan, Germany
- Thomas Schmidt
-
Affiliation Stage Cell Therapeutics, Göttingen, Germany
- Matthias Edinger
-
Affiliation Department of Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany
- Stanley R. Riddell
-
Affiliations Focus Group “Clinical Cell Processing and Purification”, Institute for Advanced Study, Technische Universität München, Munich, Germany, Program in Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
- Lothar Germeroth
-
Affiliation Stage Cell Therapeutics, Göttingen, Germany
- Dirk H. Busch
-
* E-mail: dirk.busch@mikrobio.med.tum.de
Affiliations Institute for Medical Microbiology, Immunology and Hygiene, Technische Universität München, Munich, Germany, Focus Group “Clinical Cell Processing and Purification”, Institute for Advanced Study, Technische Universität München, Munich, Germany, Clinical Cooperation Group “Antigen-specific Immunotherapy”, Helmholtz Center Munich (Neuherberg) and TUM, Munich, Germany, DZIF - National Centre for Infection Research, Munich, Germany
Competing Interests
The authors have read the journal's policy and have the following conflicts: Streptamer technology is covered by US Patent 7,776,562 (patent holder Dirk H. Busch and Hermann Wagner). CT, CP, TS, and LG are employees of STAGE Cell Therapeutics, which is developing Streptamer products for clinical applications. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: CS SD ME SRR LG DHB. Performed the experiments: CS SD CT CP JB TY M. Schiemann MN TS. Analyzed the data: CS SD DHB. Contributed reagents/materials/analysis tools: KM M. Schlapschy AS. Wrote the paper: CS SD SRR DHB.